Faster Drug Decision Buoys Novartis as Key Drugs Lose Protection

Faster Drug Decision Buoys Novartis as Key Drugs Lose Protection

Gianluca Colla/Bloomberg

A sign sits on the side of the Novartis AG headquarters in Basel.